Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2014

Open Access 01-12-2014 | Original investigation

Younger age, higher body mass index and lower adiponectin concentration predict higher serum thromboxane B2 level in aspirin-treated patients with type 2 diabetes: an observational study

Authors: Agnieszka Kaplon-Cieslicka, Marek Postula, Marek Rosiak, Michal Peller, Agnieszka Kondracka, Agnieszka Serafin, Ewa Trzepla, Grzegorz Opolski, Krzysztof J Filipiak

Published in: Cardiovascular Diabetology | Issue 1/2014

Login to get access

Abstract

Background

Evidence from the literature suggests diminished acetylsalicylic acid (ASA) treatment efficacy in type 2 diabetes (DM2). High on-aspirin platelet reactivity (HAPR) in DM2 has been linked to poor glycemic and lipid control. However, there are no consistent data on the association between HAPR and insulin resistance or adipose tissue metabolic activity. The aim of this study was to assess the relationship between laboratory response to ASA and metabolic control, insulin resistance and adipokines in DM2.

Methods

A total of 186 DM2 patients treated with oral antidiabetic drugs and receiving 75 mg ASA daily were included in the analysis. Response to ASA was assessed by measuring serum thromboxane B2 (TXB2) concentration and expressed as quartiles of TXB2 level. The achievement of treatment targets in terms of glycemic and lipid control, insulin resistance parameters (including Homeostatic Model Assessment-Insulin Resistance, HOMA-IR, index), and serum concentrations of high-molecular weight (HMW) adiponectin, leptin and resistin, were evaluated in all patients. Univariate and multivariate logistic regression analyses were performed to determine the predictive factors of serum TXB2 concentration above the upper quartile and above the median.

Results

Significant trends in age, body mass index (BMI), HOMA-IR, HMW adiponectin concentration, C-reactive protein concentration and the frequency of achieving target triglyceride levels were observed across increasing quartiles of TXB2. In a multivariate analysis, only younger age and higher BMI were independent predictors of TXB2 concentration above the upper quartile, while younger age and lower HMW adiponectin concentration were predictors of TXB2 concentration above the median.

Conclusions

These results suggest that in DM2, the most important predictor of HAPR is younger age. Younger DM2 patients may therefore require total daily ASA doses higher than 75 mg, preferably as a twice-daily regimen, to achieve full therapeutic effect. Higher BMI and lower HMW adiponectin concentration were also associated with less potent ASA effect. This is the first study to demonstrate an association of lower adiponectin concentration with higher serum TXB2 level in patients treated with ASA.
Appendix
Available only for authorised users
Literature
1.
Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL: ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013, 34: 3035-3087.CrossRefPubMed
2.
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002, 324: 71-86.
3.
Crescente M, Di Castelnuovo A, Iacoviello L, Vermylen J, Cerletti C, de Gaetano G: Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost. 2008, 99: 14-26.PubMed
4.
Simpson SH, Abdelmoneim AS, Omran D, Featherstone TR: Prevalence of high on-treatment platelet reactivity in diabetic patients treated with aspirin. Am J Med. 2014, 127: 95-e1-9CrossRefPubMed
5.
Takahashi S, Ushida M, Komine R, Shimizu A, Uchida T, Ishihara H, Shibano T, Watanabe G, Ikeda Y, Murata M: Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. Thromb Res. 2007, 119: 517-524.CrossRefPubMed
6.
Ertugrul DT, Tutal E, Yildiz M, Akin O, Yalçin AA, Ure OS, Yilmaz H, Yavuz B, Deveci OS, Ata N, Küçükazman M: Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010, 95: 2897-2901.CrossRefPubMed
7.
Mylotte D, Kavanagh GF, Peace AJ, Tedesco AF, Carmody D, O'Reilly M, Foley DP, Thompson CJ, Agha A, Smith D, Kenny D: Platelet reactivity in type 2 diabetes mellitus: a comparative analysis with survivors of myocardial infarction and the role of glycaemic control. Platelets. 2012, 23: 439-446.CrossRefPubMed
8.
DiChiara J, Bliden KP, Tantry US, Hamed MS, Antonino MJ, Suarez TA, Bailon O, Singla A, Gurbel PA: The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes. 2007, 56: 3014-3019.CrossRefPubMed
9.
Mortensen SB, Larsen SB, Grove EL, Kristensen SD, Hvas AM: Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. Thromb Res. 2010, 126: e318-e322.CrossRefPubMed
10.
Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, Golanski J, Sitkiewicz D, Pregowski J, Gorski J, Zembala M, Opolski G, Huber K, Arnesen H, Kristensen SD, De Caterina R: Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2009, 30: 426-435.CrossRefPubMed
11.
Viswanathan GN, Marshall SM, Balasubramaniam K, Badimon JJ, Zaman AG: Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome. Thromb Res. 2014, 133: 880-885.PubMedCentralCrossRefPubMed
12.
Grove EL, Gregersen S: Antiplatelet therapy in patients with diabetes mellitus. Curr Vasc Pharmacol. 2012, 10: 494-505.CrossRefPubMed
13.
Würtz M, Grove EL: Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance. Curr Pharm Des. 2012, 18: 5344-5361.CrossRefPubMed
14.
Watala C, Pluta J, Golanski J, Rozalski M, Czyz M, Trojanowski Z, Drzewoski J: Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med (Berl). 2005, 83: 148-158.CrossRef
15.
16.
Assert R, Scherk G, Bumbure A, Pirags V, Schatz H, Pfeiffer AF: Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. Diabetologia. 2001, 44: 188-195.CrossRefPubMed
17.
Russo I, Viretto M, Barale C, Mattiello L, Doronzo G, Pagliarino A, Cavalot F, Trovati M, Anfossi G: High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets. Diabetes. 2012, 61: 2913-2921.PubMedCentralCrossRefPubMed
18.
Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, Luzak B, Kropiwnicka A, Drzewoski J: Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res. 2004, 113: 101-113.CrossRefPubMed
19.
Lemkes BA, Bähler L, Kamphuisen PW, Stroobants AK, Van Den Dool EJ, Hoekstra JB, Nieuwland R, Gerdes VE, Holleman F: The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus. J Thromb Haemost. 2012, 10: 639-646.CrossRefPubMed
20.
Hovens MM, Snoep JD, Groeneveld Y, Tamsma JT, Eikenboom JC, Huisman MV: High levels of low-density lipoprotein cholesterol and triglycerides and suboptimal glycemic control predict diminished ex vivo aspirin responsiveness in patients with Type 2 diabetes. J Thromb Haemost. 2007, 5: 1562-1564.CrossRefPubMed
21.
Cohen HW, Crandall JP, Hailpern SM, Billett HH: Aspirin resistance associated with HbA1c and obesity in diabetic patients. J Diabetes Complications. 2008, 22: 224-228.CrossRefPubMed
22.
Pulcinelli FM, Biasucci LM, Riondino S, Giubilato S, Leo A, Di Renzo L, Trifirò E, Mattiello T, Pitocco D, Liuzzo G, Ghirlanda G, Crea F: COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. Eur Heart J. 2009, 30: 1279-1286.CrossRefPubMed
23.
Le Guyader A, Pacheco G, Seaver N, Davis-Gorman G, Copeland J, McDonagh PF: Inhibition of platelet GPIIb-IIIa and P-selectin expression by aspirin is impaired by stress hyperglycemia. J Diabetes Complications. 2009, 23: 65-70.CrossRefPubMed
24.
25.
26.
Basili S, Pacini G, Guagnano MT, Manigrasso MR, Santilli F, Pettinella C, Ciabattoni G, Patrono C, Davì G: Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol. 2006, 48: 2531-2538.CrossRefPubMed
27.
Yassine HN, Davis-Gorman G, Stump CS, Thomson SS, Peterson J, McDonagh PF: Clinical determinants of aspirin resistance in diabetes. Diabetes Res Clin Pract. 2010, 90: e19-e21.PubMedCentralCrossRefPubMed
28.
Graziani F, Biasucci LM, Cialdella P, Liuzzo G, Giubilato S, Della Bona R, Pulcinelli FM, Iaconelli A, Mingrone G, Crea F: Thromboxane production in morbidly obese subjects. Am J Cardiol. 2011, 107: 1656-1661.CrossRefPubMed
29.
Mehta SS, Silver RJ, Aaronson A, Abrahamson M, Goldfine AB: Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol. 2006, 97: 567-570.CrossRefPubMed
30.
Postula M, Kaplon-Cieslicka A, Rosiak M, Kondracka A, Serafin A, Filipiak KJ, Czlonkowski A, Opolski G, Janicki PK: Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: evaluation of 27 polymorphisms within candidate genes. J Thromb Haemost. 2011, 9: 2291-2301.CrossRefPubMed
31.
Kapłon-Cieślicka A, Rosiak M, Postuła M, Serafin A, Kondracka A, Opolski G, Filipiak KJ: Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes. Kardiol Pol. 2013, 71: 893-902.CrossRefPubMed
32.
Rosiak M, Postuła M, Kapłon-Cieślicka A, Trzepla E, Filipiak KJ, Członkowski A, Opolski G: The effect of doubling the dose of acetylsalicylic acid (ASA) on platelet function parameters in patients with type 2 diabetes and platelet hyperreactivity during treatment with 75 mg of ASA: a subanalysis of the AVOCADO study. Kardiol Pol. 2013, 71: 552-557.CrossRefPubMed
33.
Meen O, Brosstad F, Khiabani H, Gjertsen E, Lauritsen ME, Pedersen TM, Bjørnsen S, Schjelderup NM, Ameln W, Ng EC, Wettergreen M, Siddique SP, Erikssen G: No case of COX-1-related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography. Scand J Clin Lab Invest. 2008, 68: 185-1891.CrossRefPubMed
34.
Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, Fitzgerald DJ: Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol. 2005, 46: 1258-1263.CrossRefPubMed
35.
Frelinger AL, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD: Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation. 2009, 120: 2586-2596.CrossRefPubMed
36.
Standards of medical care in diabetes - 2014. Diabetes Care. 2014, 37: S14-S80.
37.
Dolasık I, Sener SY, Celebı K, Aydın ZM, Korkmaz U, Canturk Z: The effect of metformin on mean platelet volume in dıabetıc patients. Platelets. 2013, 24: 118-121.CrossRefPubMed
38.
Ferguson AD, Dokainish H, Lakkis N: Aspirin and clopidogrel response variability: review of the published literature. Tex Heart Inst J. 2008, 35: 313-320.PubMedCentralPubMed
39.
Hubbard RE, O'Mahony MS, Calver BL, Woodhouse KW: Plasma esterases and inflammation in ageing and frailty. Eur J Clin Pharmacol. 2008, 64: 895-900.CrossRefPubMed
40.
Singh S, Nain CK, Verma M, Leelamma CO, Goel RC: Aspirin esterases in North-West Indians: the influence of age and nutrition. Int J Clin Pharmacol Ther. 2000, 38: 315-319.CrossRefPubMed
41.
Summerbell J, Yelland C, Woodhouse K: The kinetics of plasma aspirin esterase in relation to old age and frailty. Age Ageing. 1990, 19: 128-130.CrossRefPubMed
42.
Gresner P, Dolník M, Waczulíková I, Bryszewska M, Sikurová L, Watala C: Increased blood plasma hydrolysis of acetylsalicylic acid in type 2 diabetic patients: a role of plasma esterases. Biochim Biophys Acta. 2006, 1760: 207-215.CrossRefPubMed
43.
Christensen KH, Grove EL, Würtz M, Kristensen SD, Hvas AM: Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes. Platelets. 2014, ᅟ: ᅟ-in press
44.
Henry P, Vermillet A, Boval B, Guyetand C, Petroni T, Dillinger JG, Sideris G, Sollier CB, Drouet L: 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost. 2011, 105: 336-344.CrossRefPubMed
45.
Rocca B, Santilli F, Pitocco D, Mucci L, Petrucci G, Vitacolonna E, Lattanzio S, Mattoscio D, Zaccardi F, Liani R, Vazzana N, Del Ponte A, Ferrante E, Martini F, Cardillo C, Morosetti R, Mirabella M, Ghirlanda G, Davì G, Patrono C: The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost. 2012, 10: 1220-1230.CrossRefPubMed
46.
Dillinger JG, Drissa A, Sideris G, Bal dit Sollier C, Voicu S, Manzo Silberman S, Logeart D, Drouet L, Henry P: Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. Am Heart J. 2012, 164: 600-606.CrossRefPubMed
47.
Spectre G, Arnetz L, Östenson CG, Brismar K, Li N, Hjemdahl P: Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. Thromb Haemost. 2011, 106: 491-499.CrossRefPubMed
48.
Addad F, Chakroun T, Elalamy I, Abderazek F, Chouchene S, Dridi Z, Gerotziafas GT, Hatmi M, Hassine M, Gamra H: Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes. Int J Hematol. 2010, 92: 296-301.CrossRefPubMed
49.
Capodanno D, Patel A, Dharmashankar K, Ferreiro JL, Ueno M, Kodali M, Tomasello SD, Capranzano P, Seecheran N, Darlington A, Tello-Montoliu A, Desai B, Bass TA, Angiolillo DJ: Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv. 2011, 4: 180-187.CrossRefPubMed
50.
Monteiro PF, Morganti RP, Delbin MA, Calixto MC, Lopes-Pires ME, Marcondes S, Zanesco A, Antunes E: Platelet hyperaggregability in high-fat fed rats: a role for intraplatelet reactive-oxygen species production. Cardiovasc Diabetol. 2012, 11: 5-PubMedCentralCrossRefPubMed
51.
Kim JD, Park CY, Ahn KJ, Cho JH, Choi KM, Kang JG, Kim JH, Lee KY, Lee BW, Mok JO, Moon MK, Park JY, Park SW: Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes. Atherosclerosis. 2014, 234: 146-151.CrossRefPubMed
52.
Larsen SB, Grove EL, Kristensen SD, Hvas AM: Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease. Thromb Haemost. 2013, 109: 920-999.CrossRefPubMed
53.
Davì G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, Patrono C: Platelet activation in obese women: role of inflammation and oxidant stress. JAMA. 2002, 288: 2008-2014.CrossRefPubMed
54.
Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, FitzGerald GA: Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation. 2013, 127: 377-385.PubMedCentralCrossRefPubMed
55.
Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ: Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke. 2006, 37: 2153-2158.CrossRefPubMed
56.
Peace A, McCall M, Tedesco T, Kenny D, Conroy RM, Foley D, Cox D: The role of weight and enteric coating on aspirin response in cardiovascular patients. J Thromb Haemost. 2010, 8: 2323-2325.CrossRefPubMed
57.
58.
Sulistyoningrum DC, Gasevic D, Lear SA, Ho J, Mente A, Devlin AM: Total and high molecular weight adiponectin and ethnic-specific differences in adiposity and insulin resistance: a cross-sectional study. Cardiovasc Diabetol. 2013, 12: 170-PubMedCentralCrossRefPubMed
59.
60.
Fisman EZ, Tenenbaum A: Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease?. Cardiovasc Diabetol. 2014, 13: 103-PubMedCentralCrossRefPubMed
61.
Mather KJ, Funahashi T, Matsuzawa Y, Edelstein S, Bray GA, Kahn SE, Crandall J, Marcovina S, Goldstein B, Goldberg R: Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes. 2008, 57: 980-986.PubMedCentralCrossRefPubMed
62.
Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Matsuda K, Yamaguchi M, Tanabe H, Kimura-Someya T, Shirouzu M, Ogata H, Tokuyama K, Ueki K, Nagano T, Tanaka A, Yokoyama S, Kadowaki T: A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature. 2013, 503: 493-499.CrossRefPubMed
63.
Kato H, Kashiwagi H, Shiraga M, Tadokoro S, Kamae T, Ujiie H, Honda S, Miyata S, Ijiri Y, Yamamoto J, Maeda N, Funahashi T, Kurata Y, Shimomura I, Tomiyama Y, Kanakura Y: Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol. 2006, 26: 224-230.CrossRefPubMed
64.
Restituto P, Colina I, Varo JJ, Varo N: Adiponectin diminishes platelet aggregation and sCD40L release. Potential role in the metabolic syndrome. Am J Physiol Endocrinol Metab. 2010, 298: E1072-E1077.CrossRefPubMed
65.
Hara K, Omori K, Sumioka Y, Aso Y: Spontaneous platelet aggregation evaluated by laser light scatter in patients with type 2 diabetes: effects of short-term improved glycemic control and adiponectin. Transl Res. 2012, 159: 15-24.CrossRefPubMed
66.
Elbatarny HS, Netherton SJ, Ovens JD, Ferguson AV, Maurice DH: Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: implication in obesity-associated cardiovascular diseases. Eur J Pharmacol. 2007, 558: 7-13.CrossRefPubMed
67.
Wang WQ, Zhang HF, Gao GX, Bai QX, Li R, Wang XM: Adiponectin inhibits hyperlipidemia-induced platelet aggregation via attenuating oxidative/nitrative stress. Physiol Res. 2011, 60: 347-354.PubMed
68.
Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ: Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem. 2003, 278: 45021-45026.CrossRefPubMed
69.
Addabbo F, Nacci C, De Benedictis L, Leo V, Tarquinio M, Quon MJ, Montagnani M: Globular adiponectin counteracts VCAM-1-mediated monocyte adhesion via AdipoR1/NF-κB/COX-2 signaling in human aortic endothelial cells. Am J Physiol Endocrinol Metab. 2011, 301: E1143-E1154.CrossRefPubMed
70.
Shoji T, Koyama H, Fukumoto S, Maeno T, Yokoyama H, Shinohara K, Emoto M, Shoji T, Yamane T, Hino M, Shioi A, Nishizawa Y: Platelet activation is associated with hypoadiponectinemia and carotid atherosclerosis. Atherosclerosis. 2006, 188: 190-195.CrossRefPubMed
Metadata
Title
Younger age, higher body mass index and lower adiponectin concentration predict higher serum thromboxane B2 level in aspirin-treated patients with type 2 diabetes: an observational study
Authors
Agnieszka Kaplon-Cieslicka
Marek Postula
Marek Rosiak
Michal Peller
Agnieszka Kondracka
Agnieszka Serafin
Ewa Trzepla
Grzegorz Opolski
Krzysztof J Filipiak
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2014
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-014-0112-0

Other articles of this Issue 1/2014

Cardiovascular Diabetology 1/2014 Go to the issue

Original investigation

Leptin is associated with vascular endothelial function in overweight patients with type 2 diabetes

Original investigation

Sinoatrial node dysfunction induces cardiac arrhythmias in diabetic mice

Original investigation

Activation of AMP-activated protein kinase by metformin protects human coronary artery endothelial cells against diabetic lipoapoptosis

Original investigation

DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure

Original investigation

Right ventricle free wall mechanics in metabolic syndrome without type-2 diabetes: effects of a 3-month lifestyle intervention program

Original investigation

Neck circumference and early stage atherosclerosis: the cardiometabolic risk in Chinese (CRC) study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits